In an effort to combat the ongoing opioid crisis, the Bismarck-Burleigh Public Health Department hosted a free Narcan training session.

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

For symptom management, Cleveland Clinic recommends the following: Drink enough fluids Rest Use a cool mist vaporizer and saline nasal spray Take ... breathing or a blue color to the skin ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone ... intelligence to automate the process. Anthem Blue Cross Blue Shield backtracked on imposing a anesthesia ...

With drug-overdose deaths in Nebraska more than doubling in a few years, having Narcan and knowing how to use it can be a ...

In those locations, as well as locations shaded in lighter blue, snow squalls could disrupt travel early next week. Check back to Daily Voice for updates. Snow Showers Could Cause Slippery Travel ...

The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...